SAN DIEGO, Dec. 7 /PRNewswire-FirstCall/ -- Neurocrine Biosciences, Inc. announced today that the Company has appointed Adrian Adams to its Board of Directors effective immediately. Mr. Adams is President and CEO of Kos Pharmaceuticals, Inc. .
"Adrian's extensive experience in launching major pharmaceutical global brands and developing products in many therapeutic areas will be of great benefit to Neurocrine as we embark on our commercialization program," said Gary A. Lyons, President and Chief Executive Officer of Neurocrine Biosciences. "His strategic vision and proven track record in managing pharmaceutical development as well as sales and earnings growth will be a valuable resource for Neurocrine."
Kos, one of the fastest growing pharmaceutical companies in the U.S., reported sales of $90 million in 2001 and is expected to report sales of approximately $735 million in 2005. Under Mr. Adams' direction, Kos has become fully profitable through internal strategic growth as well as through product acquisitions and in-licensing arrangements. Prior to joining Kos, Mr. Adams spent over 30 years in senior management positions with major pharmaceutical companies, including Novartis Pharmaceuticals, SmithKline Beecham and ICI Pharmaceuticals (Astra Zeneca).
Neurocrine Biosciences, Inc. is a product-based biopharmaceutical company focused on neurological and endocrine diseases and disorders. Our product candidates address some of the largest pharmaceutical markets in the world including insomnia, anxiety, depression, diabetes, multiple sclerosis, irritable bowel syndrome, eating disorders, pain, and autoimmunity. Neurocrine Biosciences, Inc. news releases are available through the Company's website via the Internet at http://www.neurocrine.com
Neurocrine Biosciences, Inc.CONTACT: Elizabeth Foster or Claudia Woodworth, +1-858-617-7600, both ofNeurocrine Biosciences, Inc.
Web site: http://www.neurocrine.com/
